Q2 FY27 revenue up 16%, EBITDA up 20% and PAT up 14%

Investor Communications View source PDF Explain this filing

ADVENZYMES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+7.6%Reaction day

₹260.00

prior close

₹271.00

announcement price

After-mkt

timing

Nifty Microcap 250market+1.4%+6.1% vs market

Biotechnology peers, median of 5sector+0.9%+6.7% vs sector

On the reaction day the stock moved 6.1 pts more than Nifty Microcap 250 and 6.7 pts more than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

+2.7

15m

+2.0

30m

+3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+7.6+1.4+6.1+0.9+6.7

Next day

+4.8+1.7+3.1+3.3+1.6

+6.9+3.9+2.9+6.8+0.1

+9.3+5.1+4.3+9.9-0.5

+8.0pendingpending+10.3-2.2

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Biotechnology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the quarter ended September 30, 2026, revenue rose 16% to ₹2,145 million, EBITDA rose 20% to ₹721 million, and profit after tax rose 14% to ₹512 million. EBITDA and PAT margins were 34% and 24%. H1 revenue rose 10% to ₹4,062 million, EBITDA rose 7% to ₹1,250 million, and PAT rose 5% to ₹897 million.

Likely market impact

Strong quarterly earnings and a 34% EBITDA margin support positive sentiment, though H1 PAT growth of 5% and mixed segment trends limit the case.